Development of 2-Methoxyhuprine as Novel Lead for Alzheimer’s Disease Therapy

Tacrine (THA), the first clinically effective acetylcholinesterase (AChE) inhibitor and the first approved drug for the treatment of Alzheimer’s disease (AD), was withdrawn from the market due to its side effects, particularly its hepatotoxicity. Nowadays, THA serves as a valuable scaffold for the d...

Descripción completa

Detalles Bibliográficos
Autores principales: Mezeiova, Eva, Korabecny, Jan, Sepsova, Vendula, Hrabinova, Martina, Jost, Petr, Muckova, Lubica, Kucera, Tomas, Dolezal, Rafael, Misik, Jan, Spilovska, Katarina, Pham, Ngoc Lam, Pokrievkova, Lucia, Roh, Jaroslav, Jun, Daniel, Soukup, Ondrej, Kaping, Daniel, Kuca, Kamil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152224/
https://www.ncbi.nlm.nih.gov/pubmed/28788095
http://dx.doi.org/10.3390/molecules22081265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6152224/
https://www.ncbi.nlm.nih.gov/pubmed/28788095
http://dx.doi.org/10.3390/molecules22081265

Ejemplares similares